Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHIFT-2: Aflibercept in Wet AMD
NCT02002377Phase 4Terminated
- Sponsor
- Unity Health Toronto
- Start
- Apr 2014
- Primary completion
- Feb 2017
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in exudative macular degeneration, sponsored by Unity Health Toronto. Started Apr 2014; status: terminated.
02
Drugs
aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT02002377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02002377.